PROCEPT BioRobotics Corp (NASDAQ: PRCT)

PROCEPT BioRobotics Corp, a surgical robotics company (NASDAQ: PRCT), is dedicated to transforming patient care in the field of urology. The company's primary business activities revolve around the development, manufacture, and sale of the AquaBeam Robotic System, an advanced, image-guided surgical robotic system specifically designed for minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). BPH is a prevalent prostate disease, affecting approximately 40 million men in the United States alone.

The AquaBeam Robotic System utilizes a single-use disposable handpiece to deliver PROCEPT BioRobotics Corp's proprietary Aquablation therapy. This therapy combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The system is engineered to facilitate consistent and reproducible BPH surgery outcomes.

PROCEPT BioRobotics Corp generates revenue primarily through the sale of its AquaBeam Robotic System to hospitals. These hospitals then bill various third-party payors for reimbursement for the procedures performed using the system. The company's primary customers are urologists who perform hospital-based resective BPH surgery.

The company's competitive advantages stem from its proprietary Aquablation therapy, which offers a unique combination of benefits. These include significant and durable symptom relief, a favorable safety profile, resection independent of prostate size and shape and surgeon experience, personalized treatment planning, and targeted and controlled resection with consistent resection times. PROCEPT BioRobotics Corp's strong presence in the urology market, coupled with its established relationships with key opinion leaders (KOLs) within the urology community and collaboration with key urological societies in global markets, further solidifies its position in the industry.

The AquaBeam Robotic System and Aquablation therapy offer a distinctive combination of benefits, making them compelling options for treating BPH. PROCEPT BioRobotics Corp's focus on developing transformative solutions in urology, its established relationships within the industry, and its growing installed base of AquaBeam Robotic Systems position it for continued growth and success in the industry.

However, it's important to note that PROCEPT BioRobotics Corp operates within a heavily regulated environment. In the United States, the company's products are subject to regulation as medical devices under the Federal Food, Drug, and Cosmetic Act (FDCA), enforced by the FDA. The company's products are classified into one of three classes based on the degree of risk and the level of manufacturer and regulatory control needed. The company's currently marketed AquaBeam Robotic System is a Class II device, initially granted marketing authorization through a de novo classification. Subsequent modifications to the system have received FDA clearance via a 510(k) premarket notification, using the initially authorized device as the predicate device.

Clinical trials are a crucial part of PROCEPT BioRobotics Corp's operations, often required to support premarket approval (PMA) or de novo requests and sometimes required for 510(k) submissions. These trials must comply with the FDA's investigational device exemption (IDE) regulations. Post-market, the company is subject to numerous regulatory requirements, including establishment registration.